for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Clinica Baviera SA

CBAV.MC

Latest Trade

8.80EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

8.60

 - 

14.65

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
8.80
Open
--
Volume
--
3M AVG Volume
0.03
Today's High
--
Today's Low
--
52 Week High
14.65
52 Week Low
8.60
Shares Out (MIL)
16.30
Market Cap (MIL)
144.32
Forward P/E
9.94
Dividend (Yield %)
--

Latest Developments

More

Clinica Baviera H1 Net Profit At 3.1 Mln Euros, Down 57% YoY

Clinica Baviera Q1 Net Profit Down 41.8% At 2.1 Mln Euros YoY

Clinica Baviera Updates 2020 Targets Due To Impact Of Covid-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Clinica Baviera SA

Clinica Baviera SA is a Spain-based company engaged in the healthcare sector. The Company focuses on providing services within the field of ophthalmic medicine. The Company is specialized in the diagnosis and treatment of eye disorders, including myopia, hyperopia, astigmatism, cataracts, glaucoma, vitreous-retina and strabismus, among others. The Company operates a network of clinics located in various European countries, such as Spain, Germany, Austria and Italy. In addition, the Company is a parent of the Baviera Group, a group that comprises a number of controlled entities, including Clinica Baviera Italia Srl, Clinica Baviera Mallorca SL, Care Vision Germany GmbH and Castellana de Intermediacion Sanitaria SL, among others. The main shareholder of the Company is Aier Eye International (Europe) Slu.

Industry

Healthcare Facilities

Contact Info

Paseo de la Castellana n 20

MADRID, MAD

28046

Spain

+34.917.819880

https://www.clinicabaviera.com/

Executive Leadership

Bang Chen

Chairman of the Board

Eduardo Baviera Sabater

Chief Executive Officer, Executive Director

Virgilio Leal Espi

Chief Financial Officer

Marcos Bueso Sanchis

General Director

Sofia Querol Videgain

Director of Medical Management Unit

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2019

0.1K

2020(E)

0.1K
EPS (EUR)

2019

0.780

2020(E)

0.890
Price To Earnings (TTM)
16.54
Price To Sales (TTM)
1.29
Price To Book (MRQ)
4.29
Price To Cash Flow (TTM)
6.45
Total Debt To Equity (MRQ)
57.70
LT Debt To Equity (MRQ)
39.56
Return on Investment (TTM)
12.00
Return on Equity (TTM)
8.60

Latest News

Latest News

BRIEF-Clinica Baviera Q1 Net Profit Down 41.8% At 2.1 Mln Euros YoY

* SAID ON THURSDAY Q1 REVENUE 29.4 MILLION EUROS VERSUS 29.7 MILLION EUROS YEAR AGO

BRIEF-Clinica Baviera Updates 2020 Targets Due To Impact Of Covid-19

* SEES 2020 EBITDA MARGIN IN EUROPE OF 5.2%, NET LOSS IN EUROPE AT 1.9 MILLION EUROS Further company coverage: (Gdansk Newsroom)

BRIEF-Clinica Baviera To Restart Activity And To End Temporary Layoffs

* TO RESTART ACTIVITY AND TO END TEMPORARY LAYOFFS (ERTE) OF EMPLOYEES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Clinica Baviera Implements Temporary Layoffs For 87% Of Its Total Workforce In Spain

* SAID ON TUESDAY IT HAD IMPLEMENTED TEMPORARY LAYOFFS DUE TO FORCE MAJEURE, WHICH AFFECTS CLINIC STAFF REPRESENTING 87% OF THE GROUP'S TOTAL WORKFORCE IN SPAIN

BRIEF-Clinica Baviera Temporarily Limits Activity In All Its Clinics Located In Spain

* SAYS TO PROCEED WITH THE TEMPORARY LIMITATION OF THE ACTIVITY IN ALL ITS CLINICS LOCATED IN SPAIN FOR 15 DAYS

BRIEF-Clinica Baviera FY EBITDA Up 43.7% YoY

* FY EBITDA 31.5 MILLION EUROS, UP 43.7% YEAR ON YEAR Source text: https://bit.ly/2HY8oMW Further company coverage: (Gdansk Newsroom)

BRIEF-Clinica Baviera FY Net Profit Up At 12.8 Mln Euros YoY

* FY NET SALES 124.3 MILLION EUROS VERSUS 109.3 MILLION EUROS YEAR AGO

BRIEF-Clinica Baviera's Board Approves Removal Of Marcos Bueso Sanchis As General Director

* BOARD APPROVES REMOVAL OF MARCOS BUESO SANCHIS AS GENERAL DIRECTOR EFFECTIVE AS OF APRIL 3, 2020 Source text: https://bit.ly/2Tf4ynK Further company coverage: (Gdansk Newsroom)

BRIEF-Clinica Baviera Sees Annual Sales Growth Of About 9 Pct In 2018-2020

* SEES 2020 SALES OF 130 MILLION EUROS, EBITDA MARGIN OF 22 PERCENT, NET PROFIT OF 16.5 MILLION EUROS

BRIEF-Clinica Baviera Q1 Net Profit Up 52 Pct YoY

* Q1 NET PROFIT 4.0 MILLION EUROS VERSUS 2.6 MILLION EUROS YEAR AGO

BRIEF-Clinica Baviera To Propose Dividend Of 0.48 Euros Gross/Shr

* SAYS TO PROPOSE DIVIDEND OF 0.48 EUROS GROSS PER SHARE TO BE PAID ON MAY 25 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Clinica Baviera SA To Propose Dividends Corresponding To 80 Pct Of Its Net Profit

* SAYS TO PROPOSE DIVIDENDS CORRESPONDING TO 80 PERCENT OF ITS NET PROFIT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Clinica Baviera FY EBITDA Up 9.3 Pct YoY

* FY NET PROFIT 9.8 MILLION EUROS VERSUS 7.9 MILLION EUROS YEAR AGO

BRIEF-Clinica Baviera Says Aier Eye Hospital's Board Authorizes Acquisition Of Co's Shares

* BOARD OF AIER EYE HOSPITAL GROUP AUTHORIZES ACQUISITION OF CO'S SHARES BY AIER EYE INTERNATIONAL (EUROPE)

BRIEF-Aier Eye Hospital Group's board authorizes general manager to buy stake in Clínica Baviera for up to 2 mln euros

* Says its board authorizes general manager to buy stake in Clínica Baviera, S.A., for up to 2 million euros within 12 months

BRIEF-Clinica Baviera 9-month net profit up 7.5 pct YoY

* 9-MONTH NET PROFIT 6.6 MILLION EUROS VERSUS 6.1 MILLION EUROS YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up